Results 131 to 140 of about 20,867 (266)

Intestinal epithelial injury and inflammation after physical work in temperate and hot environments in older men with hypertension or type 2 diabetes

Experimental Physiology, EarlyView.
Abstract We tested whether older adults with well‐controlled type 2 diabetes or hypertension, compared with age‐matched adults without chronic disease, exhibit greater intestinal damage, microbial translocation and inflammation during exertional heat stress.
Ben J. Lee, Tessa R. Flood, Sophie L. Russell, James J. McCormick, Kelli E. King, Naoto Fujii, Tatsuro Amano, Sean Notley, Glen P. Kenny   +8 more
wiley   +1 more source

(Dis)agreement and concordance of metabolic indices from the oral glucose tolerance test and mixed‐meal tolerance test: Implications for application

Experimental Physiology, EarlyView.
Abstract Metabolic indices derived from the oral glucose tolerance test (OGTT) and mixed‐meal tolerance test (MMTT) are often interpreted interchangeably; however, these tests represent distinct physiological stimuli. In order to examine potential differential metabolic responses to these tests, we characterized the (dis)agreement between OGTT‐ and ...
Nina Sloth Nielsen, Nikolaj Agerlin, Nikolas Antoniou, Helga Ellingsgaard, Kristian Karstoft, Louise Lang Lehrskov, Grit Elster Legård, Mark Preben Printz Lyngbæk, Beckey Trinh, Thomas P. J. Solomon, Marc Y. Donath, Mathias Ried‐Larsen, Cody Garett Durrer   +12 more
wiley   +1 more source

c-Jun N-terminal kinase 3 as a permissive regulator of β-cell incretin responsiveness. [PDF]

J Diabetes Investig
Yamazaki Y.
europepmc   +1 more source

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Changes in incretin hormone concentrations after pancreaticoduodenectomy: a systematic review and exploratory meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Grząsiak-Kraj O, Kraj T, Poznański K, Szmiel A, Strzelczyk J.   +4 more
europepmc   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

The Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild, Valdemar Brimnes Ingemann Johansen, Christoffer Clemmensen, Pablo Ranea‐Robles   +3 more
wiley   +1 more source

Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States

Diabetes, Metabolic Syndrome and Obesity
Sriya Amruta Kosaraju,1 Rong M Zhang2 1Department of Biomedical Sciences, University of Missouri-Kansas City, Kansas City, MO, USA; 2Department of Medicine-Division of Endocrinology, Washington University, St Louis, MO, USACorrespondence: Rong M Zhang ...
Kosaraju SA, Zhang RM
doaj  

A Review of Lifestyle Interventions Provided as an Adjunct to Obesity Management Medications

Obesity Science &Practice, Volume 12, Issue 4, August 2026.
ABSTRACT Objective This review synthesized the components of lifestyle interventions that have been provided in Phase 3 trials of obesity management medications (OMMs). Methods PubMed, CINAHL, and EMBASE were searched for Phase 3 clinical trials published from inception to February 2026 that tested FDA‐approved OMMs.
Ariana M. Chao, Ransford Asante, Maame Efua Sersah, Umar Anwar Jahangir, Alexandra Peary, Daniel Kudaya   +5 more
wiley   +1 more source

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy. [PDF]

Indian J Med Res
Gupta M, Shukla J.
europepmc   +1 more source

Inhibition of peripheral CB1 receptors modulates food intake and metabolic efficiency in obesity independently of the gut–brain vagal axis

British Journal of Pharmacology, Volume 183, Issue 16, Page 4953-4968, August 2026.
Background and Purpose Obesity involves profound disruptions in neuronal circuits, neuroendocrine communication and the endocannabinoid system. While global blockade of cannabinoid CB1 receptors improves metabolism, its clinical use is limited by neuropsychiatric side effects.
Oriane Onimus, Camille de Almeida, Benoit Bertrand, Julien Castel, Nejmeh Mashhour, Anthony Ansoult, Serge Luquet, Giuseppe Gangarossa   +7 more
wiley   +1 more source